AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: FASENRA (AstraZeneca) (fasenra.com)
FASENRA presents a high-substance clinical narrative that effectively neutralizes its marketing fluff with granular, FDA-audited trial data. The site is a rare example of a drug brand that prioritizes technical dosing protocols and quantified outcomes over generic emotional appeals. Its only significant failures are technical, specifically the lack of modern structured data to anchor its authority in the semantic web.
Implement MedicalWebPage and Organization schema to formally link the product to AstraZeneca and regulatory bodies. Add direct outbound links to ClinicalTrials.gov for each study referenced in the footnotes to provide a neutral verification path. Include Person schema for patient stories and named experts to remove the ‘unverifiable expert’ penalty. Update the patient treated count with a ‘current as of’ date to avoid credibility decay as the temporal anchor shifts beyond 2026.
The information density is exceptionally high, with body text focusing on specific clinical metrics such as the 51 percent reduction in asthma attacks and a 75 percent reduction in daily oral steroid use. While some headings like [H1] ‘FASENRA is proven to help you breathe better’ utilize generic power words, they are immediately anchored by technical nouns and starter dose schedules. Substance is prioritized over fluff, cited by exact attack rates per year (0.74 vs 1.52) and patient population counts (160,000). Concept repetition is present but serves as a regulatory reinforcement of the primary value proposition rather than content padding.
Parameter drift, trailing slash inconsistencies, and language leaks create unintended alternate identities. Get a Clinical Canonical Diagnosis to reveal where duplicate embeddings are silently created.
There is zero semantic drift across the four pages analyzed. The homepage promise of fewer asthma attacks is quantitatively proved on the ‘Why FASENRA’ page through 48-week and 56-week clinical trial data. The dosing signals on the homepage (every 8 weeks) are perfectly aligned with the technical ‘Taking FASENRA’ page which details the ‘3 starter doses’ requirement. The site remains strictly within its therapeutic area without making the over-extended breakthrough claims common in lower-substance biotech startups.
Our Authority as a Service model transforms raw diagnostic data into high stakes results. Start your Clinical Strategic Diagnosis for 1 Euro to secure the strategic fixes required for growth.
Trust theatre is minimal, though the presence of an unlinked review_count (1 or 2) across pages suggests an internal feedback metric that lacks a verified third-party proof path. Bold performance claims like ‘proven to reduce occurrence’ are heavily footnoted, though these link primarily to internal prescribing information rather than external peer-reviewed repositories like PubMed. The trust_theatre_flag remains low because the efficacy claims are regulated by pharmaceutical standards rather than social proof marketing.
The ratio of verifiable evidence to assertions is high, with 12 distinct data points identified including trial durations, median reduction percentages, and specific age indications (6 years and older). Each efficacy claim is accompanied by a symbol (§, ||, ‡) that maps to a detailed trial description. Vague assertions are nearly non-existent outside of the ‘Start the journey’ marketing transitions.
To see how the methodology translates into real diagnostic output, review a full executive level analysis applied to a global fashion retailer. View the Mango Executive SEO Strategy for a concrete example of how structural gaps, semantic weaknesses, and conversion friction are surfaced in practice.
The site matches over 10 industry jargon terms including ‘mechanism of action,’ ‘biologic treatment,’ and ‘clinical trial program.’ The value proposition is non-commodity due to the specific 8-week dosing differentiation, which is clearly positioned against standard daily maintenance therapies. Template language is primarily found in the mandated safety footers, though the ‘Patient Resources’ and ‘About’ sections are standard pharma boilerplate.
Authority gaps are the largest driver of the score due to a total absence of structured data (schema_json is null) and the use of unverified patient stories like ‘Brandi’ without Person schema or sameAs links. While the clinical authority of AstraZeneca is implied, there are no digital footprints provided for the specialists (allergists/pulmonologists) referenced as experts. The technical implementation also contains a minor credibility gap with a skipped heading hierarchy (H3 to H5).
There is no disconnect between marketing tone and demonstrated results. Every efficacy claim, such as ‘improve lung function,’ is supported by a specific percentage or a reference to a 28-week clinical trial versus placebo. The site avoids the ‘Science-driven solutions’ cliché by actually providing the science (e.g., targeting blood eosinophils levels ≥150 cells per microliter).
Medical Devices, Pharma & Biotech BS: FASENRA (AstraZeneca) (fasenra.com)
The site is an exact match for the pharmaceutical and biotech industry, adhering to strict FDA-mandated structures such as the Important Safety Information (ISI) blocks and detailed indications for use. The language is technically precise, utilizing category-specific terminology like biologic, subcutaneous, and eosinophilic asthma.
AI cannot build a coherent graph if the same page resolves into multiple identities. Explore the URL & Canonical Hygiene Technical Framework to understand how identity stability prevents duplicate embeddings and semantic drift.
“The score of 25 reflects a low BS environment. The primary penalties come from the Identity and Authority pillar (9 points) due to missing schema and the Trust and Proof pillar (5 points) for citing internal review counts without external verification. The site achieved a perfect 0 in Semantic Coherence, indicating absolute alignment between its marketing signals and clinical substance.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 30, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at FASENRA (AstraZeneca) to view the most current version of their content and see directly what the company offers.